ClinicalTrials.gg
CompletedNCT05112094Updated Oct 16, 2026

Peripheral Magnetic Stimulation to Treat Patient With Post-stroke Shoulder-hand Syndrome

An interventional study of peripheral magnetic stimulation and physical therapy in Reflex Sympathetic Dystrophy of Upper Limb and Stroke, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
20 Years to 100 Years
Sex
All
01

Study summary

Shoulder-hand syndrome is a common complication following stroke, constituting of excessive pain, swelling, heat, limited range of motion, and trophic change of the affected limbs. It not only has an extensive negative impact on both physical and psychological aspects of a stroke patient's well-being, but also impose burden on the health care system and the patient's family. Despite its relatively high incidence, there is neither well-established treatment protocol, nor high quality evidence for a single effective treatment. The objective of the present study is to investigate the efficacy, including pain, spasticity, and subluxation reduction, muscle strengthening, and shoulder range of motion improvement, of high-intensity peripheral magnetic stimulation generated by the super-inductive system to treat patients with post-stroke shoulder-hand syndrome.

Read the detailed description

The present study aims to investigate the therapeutic effects achieved by the peripheral magnetic stimulation for treating post-stroke shoulder-hand syndrome. The investigators plan to use high-intensity peripheral magnetic stimulation generated by the super-inductive system for treatment of post-stroke shoulder-hand syndrome. In terms of study design, the treatment group will receive 10 sessions of high-intensity peripheral magnetic stimulation 5 days a week for 2 weeks, with physical and occupational therapy kept as usual; while the control group will only receive conventional physical and occupational therapy. Comprehensive assessment, including history taking and physical examination testing for muscle strength, spasticity, shoulder range of motion, before and after the intervention will be conducted for evaluation.

02

Conditions studied

  • Reflex Sympathetic Dystrophy of Upper Limb
  • Stroke

Keywords

  • shoulder pain
  • magnetic stimulation
  • electric stimulation
  • reflex sympathetic dystrophy
03

In context

Reflex Sympathetic Dystrophy

43 studies on the registry are indexed under Reflex Sympathetic Dystrophy; 4 are open to participants now.

This study's enrollment of 25 is below the median of 48 across 35 interventional studies indexed under Reflex Sympathetic Dystrophy.

Browse Reflex Sympathetic Dystrophy studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >=20 years old
  • Stroke in recent 6 months
  • Clear consciousness
  • Clinical diagnosis of post-stroke shoulder-hand syndrome

Exclusion criteria

Exclusion criteria:

  • Acute bursitis, tendonitis or tendon tear
  • Fracture, dislocation or joint infection within 3 months
  • at treatment site
  • Seizure
  • Prosthesis or implant at treatment site
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    peripheral magnetic stimulation

    peripheral magnetic stimulation (50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) + physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)

    Device: peripheral magnetic stimulation · Other: physical therapy

  • Placebo comparator
    physical therapy only

    regular physical therapy (shoulder range of motion exercise and stretching 30-40 minutes per day)

    Other: physical therapy

Interventions

  • Deviceperipheral magnetic stimulation

    peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)

  • Otherphysical therapy

    regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)

06

What researchers measure

Primary outcomes

  1. pain

    change of 10-point Visual Analog Scale (0-10, higher scores mean a worse outcome)

    Time frame: 0,7, 14,28 days

Secondary outcomes

  1. strength of upper limb

    change of score of Manual muscle testing (0-5, higher scores mean a better outcome)

    Time frame: 0,7, 14,28 days

  2. spasticity of upper limb

    change of Modified Ashworth Scale (0-4, higher scores mean a worse outcome)

    Time frame: 0,7, 14,28 days

  3. range of motion of shoulder

    Change in range of motion in degree in flexion, abduction, external and internal rotation (0-180 degrees,higher scores mean a better outcome)

    Time frame: 0,7, 14,28 days

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2022, 11 months.

Of 15 interventional studies with no phase under Reflex Sympathetic Dystrophy, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 11 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Aug 2021 → Jul 2021 and completion Jun 2022 → Nov 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2021
First posted
Nov 8, 2021
StartActual
Jul 22, 2021was Aug 2021
Primary completionActual
Jun 29, 2022
CompletionActual
Nov 20, 2023was Jun 2022
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 16, 2026
Start date
Aug 1, 2021→Jul 22, 2021
Oct 16, 2026
Study completion
Jun 2022→Nov 20, 2023 (actual)
Oct 16, 2026
Enrollment
40 (estimated)→25 (actual)
Oct 16, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • Descriptionrange of motion of shoulder: how it is measured was reworded
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Status unknown→Completed
    Start date Aug 1, 2021→Jul 22, 2021
    Study completion Jun 2022→Nov 20, 2023 (now actual)
    Enrollment 40 (estimated)→25 (actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionrange of motion of shoulder: how it is measured was reworded
    + 5 other changes: verification date, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05112094
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Jul 22, 2021
Primary completion
Jun 29, 2022
Completion
Nov 20, 2023
Last update
Oct 16, 2026

Study contacts

Ming Yen Y Hsiao, MDPHD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion